title: Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease.
abstract: BACKGROUND
  The safety and efficacy of combination of platinum agents plus etoposide for patients with small cell lung cancer (SCLC) with pre-existing interstitial lung disease (ILD) is uncertain.
  
  
  METHODS
  Fifty-two patients received platinum agents plus etoposide as first-line chemotherapy for SCLC with pre-existing ILD. The clinical characteristics, treatment outcome and survival of these patients were retrospectively reviewed.
  
  
  RESULTS
  During first-line chemotherapy, only one (2%) out of the 52 patients developed an acute exacerbation of ILD. The median number of treatment cycles was four. The overall response rate was 69%. The median progression-free survival period was 4.5 months. The median survival time was 9.4 months. Thirty-three patients (63%) received at least one subsequent chemotherapy regimen, and five of these patients developed acute exacerbation of ILD.
  
  
  CONCLUSIONS
  The combination of platinum agents plus etoposide is feasible and effective in SCLC patients with pre-existing ILD, compared with regimens after second-line chemotherapy.
authors.affiliation: Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. tatyoshi@east.ncc.go.jp
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yoshida
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Yoh
authors.forename: Koichi
authors.initials: K
authors.lastname: Goto
authors.forename: Seiji
authors.initials: S
authors.lastname: Niho
authors.forename: Shigeki
authors.initials: S
authors.lastname: Umemura
authors.forename: Hironobu
authors.initials: H
authors.lastname: Ohmatsu
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Ohe
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000150:complications*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000401:mortality
chemical_list: D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin